The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Novartis to Test Efficacy of Old Malaria Drug Against COVID-19

Novartis to Test Efficacy of Old Malaria Drug Against COVID-19

April 21, 2020 • By John Miller

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ZURICH (Reuters)—Swiss drugmaker Novartis AG says it will test the malaria drug hydroxychloroquine (HCQ) in a randomized trial to see if the much talked about medicine is actually effective against COVID-19, the illness caused by the novel coronavirus.

You Might Also Like
  • CVS to Prevent Stockpiling of Malaria Drug Amid COVID-19
  • Roche Gets FDA Nod for Trial to Test Arthritis Drug on COVID-19 Patients
  • Hydroxychloroquine for COVID-19 Fails Another Test

The company hopes to have data on its efficacy by June, a lead researcher for the trial tells Reuters.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The decades-old generic medicine has been touted by U.S. President Donald Trump and others as a “game changer” treatment for the highly contagious respiratory illness, and the U.S. Food and Drug Administration (FDA) authorized it use in COVID-19 on an emergency basis. But there is not yet scientific proof that it works.

There are currently no approved medicines or vaccines specifically for COVID-19.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“Right now, we’re in a sea of anecdotes, and a lot of non-professional, poorly-informed people are making recommendations that are swaying how the public and patients view this [drug],” Richard Chaisson, MD, the Johns Hopkins University professor leading the trial, says in an interview.

Novartis says it got the go-ahead from the FDA for the trial and it hopes to start recruiting 440 patients within weeks at more than a dozen U.S. sites. Results will be reported as soon as possible, the company adds.

Use of the drug, which is also approved to treat lupus and rheumatoid arthritis, has soared since Trump started promoting it. But critics have expressed concern that the administration’s advocacy for an unproven medicine has short-circuited the FDA’s oversight process.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“We recognize the importance of answering the scientific question of whether HCQ will be beneficial for patients with COVID-19 disease,” says John Tsai, Novartis’s top drug developer. “We mobilized quickly to address this question in a randomized, double-blind, placebo-controlled study.”

Companies, such as Novartis, Roche and Gilead Sciences, are testing older medicines developed to treat other diseases, for signs they could be repurposed to tackle the coronavirus epidemic. Gilead just expanded a trial of its antiviral drug remdesivir, which previously failed as a treatment for Ebola.

Still, some fear the championing of HCQ for COVID-19 has overshadowed potentially dangerous side effects, such as vision loss and heart problems. Novartis Chief Executive Vas Narasimhan has also says the medicine is one of his biggest hopes against the pandemic.

Dr. Chaisson says many of the clinical trials to research the drug are “either small or uncontrolled or overly ambitious.” He says the Novartis trial is designed to test the drug’s effectiveness quickly, and could yield results in June.

Pages: 1 2 | Single Page

Filed Under: Drug Updates Tagged With: coronavirus, COVID-19, Hydroxychloroquine (HCQ), Novartis AG

You Might Also Like:
  • CVS to Prevent Stockpiling of Malaria Drug Amid COVID-19
  • Roche Gets FDA Nod for Trial to Test Arthritis Drug on COVID-19 Patients
  • Hydroxychloroquine for COVID-19 Fails Another Test
  • U.S. FDA Says HCQ & Other Malaria Drugs in Shortage as COVID-19 Drives Up Demand

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.